L1TD1 - a prognostic marker for colon cancer.
Biomarkers
Colon cancer
Human L1TD1 gene
Prognostic factors
Survival analysis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
19
12
2018
accepted:
18
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
15
2
2020
Statut:
epublish
Résumé
Prognostic markers specific to a particular cancer type can assist in the evaluation of survival probability of patients and help clinicians to assess the available treatment modalities. Gene expression data was analyzed from three independent colon cancer microarray gene expression data sets (N = 1052). Survival analysis was performed for the three data sets, stratified by the expression level of the LINE-1 type transposase domain containing 1 (L1TD1). Correlation analysis was performed to investigate the role of the interactome of L1TD1 in colon cancer patients. We found L1TD1 as a novel positive prognostic marker for colon cancer. Increased expression of L1TD1 associated with longer disease-free survival in all the three data sets. Our results were in contrast to a previous study on medulloblastoma, where high expression of L1TD1 was linked with poor prognosis. Notably, in medulloblastoma L1TD1 was co-expressed with its interaction partners, whereas our analysis revealed lack of co-expression of L1TD1 with its interaction partners in colon cancer. Our results identify increased expression of L1TD1 as a prognostic marker predicting longer disease-free survival in colon cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Prognostic markers specific to a particular cancer type can assist in the evaluation of survival probability of patients and help clinicians to assess the available treatment modalities.
METHODS
METHODS
Gene expression data was analyzed from three independent colon cancer microarray gene expression data sets (N = 1052). Survival analysis was performed for the three data sets, stratified by the expression level of the LINE-1 type transposase domain containing 1 (L1TD1). Correlation analysis was performed to investigate the role of the interactome of L1TD1 in colon cancer patients.
RESULTS
RESULTS
We found L1TD1 as a novel positive prognostic marker for colon cancer. Increased expression of L1TD1 associated with longer disease-free survival in all the three data sets. Our results were in contrast to a previous study on medulloblastoma, where high expression of L1TD1 was linked with poor prognosis. Notably, in medulloblastoma L1TD1 was co-expressed with its interaction partners, whereas our analysis revealed lack of co-expression of L1TD1 with its interaction partners in colon cancer.
CONCLUSIONS
CONCLUSIONS
Our results identify increased expression of L1TD1 as a prognostic marker predicting longer disease-free survival in colon cancer patients.
Identifiants
pubmed: 31337362
doi: 10.1186/s12885-019-5952-2
pii: 10.1186/s12885-019-5952-2
pmc: PMC6651905
doi:
Substances chimiques
Biomarkers, Tumor
0
L1TD1 protein, human
0
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
727Subventions
Organisme : Academy of Finland
ID : 265723
Organisme : Academy of Finland
ID : 250114, 292335, 294337, 292482, and 31444
Organisme : Academy of Finland
ID : 296801, 304995, 310561 and 313343
Organisme : European Research Council
ID : 677943
Pays : International
Organisme : H2020 European Research Council
ID : 675395
Organisme : Juvenile Diabetes Research Foundation International
ID : 2-2013-32
Références
Gastric Cancer. 2016 Jan;19(1):85-97
pubmed: 25532910
Oncogene. 2014 May 15;33(20):2655-64
pubmed: 23770853
PLoS One. 2011;6(5):e20461
pubmed: 21637830
Stem Cells. 2012 Mar;30(3):452-60
pubmed: 22162396
Clin Cancer Res. 2009 Dec 15;15(24):7642-7651
pubmed: 19996206
Gynecol Oncol. 2015 Jun;137(3):529-37
pubmed: 25858696
PLoS One. 2013 Jul 29;8(7):e70298
pubmed: 23922970
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
J Clin Oncol. 2009 Nov 1;27(31):5240-7
pubmed: 19770384
PLoS One. 2011 Apr 29;6(4):e19355
pubmed: 21559406
Cell Adh Migr. 2009 Oct-Dec;3(4):334-6
pubmed: 19949308
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Neoplasma. 2016;63(5):681-6
pubmed: 27468871
Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):333-40
pubmed: 19287074
Cell Tissue Res. 2014 Feb;355(2):365-74
pubmed: 24310606
Oncogene. 2003 May 29;22(22):3424-30
pubmed: 12776194
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
J Biol Chem. 2011 Dec 16;286(50):43123-33
pubmed: 22027835
Oncotarget. 2015 Jun 30;6(18):16168-82
pubmed: 25965823
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Mol Cancer Ther. 2016 Jun;15(6):1301-10
pubmed: 26944921
Mol Carcinog. 2016 Nov;55(11):1822-1832
pubmed: 26513225
Cancer. 2015 May 15;121(10):1570-80
pubmed: 25603912
Int J Cancer. 2007 Apr 1;120(7):1598-602
pubmed: 17205510
Am J Pathol. 2011 Sep;179(3):1110-9
pubmed: 21723846
Sci Rep. 2017 Jul 19;7(1):5823
pubmed: 28725043
Cancer Res. 2015 Aug 1;75(15):3087-97
pubmed: 26045166
Cancer Biol Ther. 2008 Jan;7(1):70-5
pubmed: 17938577
Stem Cells Dev. 2015 Nov 15;24(22):2700-8
pubmed: 26159230
Oncotarget. 2015 Aug 21;6(24):20312-26
pubmed: 26015410
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17778-83
pubmed: 24128763
Br J Cancer. 2014 Nov 11;111(10):1993-2002
pubmed: 25211665
Cancer Biol Ther. 2010 Feb;9(4):295-302
pubmed: 20026903
Stem Cell Reports. 2015 Mar 10;4(3):519-28
pubmed: 25702638
Nat Genet. 2008 May;40(5):499-507
pubmed: 18443585
J Hematol Oncol. 2016 Jul 21;9(1):57
pubmed: 27439973
Cancer Res. 2006 Jan 15;66(2):820-7
pubmed: 16424014
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20569-74
pubmed: 24259714
Gastrointest Cancer Res. 2007 Nov;1(6):237-46
pubmed: 19262902
Clin Cancer Res. 2008 Jul 1;14(13):4085-95
pubmed: 18593985
Gastroenterology. 2010 Mar;138(3):958-68
pubmed: 19914252